

119. Lisa Eisman, Norwalk, Connecticut, Court of Federal Claims No: 20–1664V
120. William Ranks, Camp Verde, Arizona, Court of Federal Claims No: 20–1665V
121. Nancy Richmond, Greenville, North Carolina, Court of Federal Claims No: 20–1666V
122. Carol Kempkes, Des Moines, Iowa, Court of Federal Claims No: 20–1667V
123. Anna-Lis Seevers, Big Rapids, Michigan, Court of Federal Claims No: 20–1669V
124. Lisa Jackson, Englewood, Ohio, Court of Federal Claims No: 20–1670V
125. Marilyn Duncan, Burkesville, Kentucky, Court of Federal Claims No: 20–1671V
126. Mary Brown, Frankenmuth, Michigan, Court of Federal Claims No: 20–1672V
127. Nina Watkins, Upper Marlboro, Maryland, Court of Federal Claims No: 20–1673V
128. Thomas Ross, Olmsted Township, Ohio, Court of Federal Claims No: 20–1674V
129. Michele Hunter, Torrington, Connecticut, Court of Federal Claims No: 20–1675V
130. Jacqueline Bowling, Pikeville, Kentucky, Court of Federal Claims No: 20–1676V
131. Janet Sincebaugh, Williamsville, New York, Court of Federal Claims No: 20–1677V
132. Stacey Neves on behalf of I. N., New York, New York, Court of Federal Claims No: 20–1678V
133. Elisabeth Preitauer, Wichita Falls, Texas, Court of Federal Claims No: 20–1679V
134. Dominick Clemente, Brooklyn, New York, Court of Federal Claims No: 20–1680V
135. Theresa Jackson, Boston, Massachusetts, Court of Federal Claims No: 20–1681V
136. Charles Edwards, Lumberton, Texas, Court of Federal Claims No: 20–1682V
137. Charles Edwards, Lumberton, Texas, Court of Federal Claims No: 20–1683V
138. Barbara Lytes-Williams, Batesburg, South Carolina, Court of Federal Claims No: 20–1684V
139. Yaneth Garcia on behalf of A.M., Williamsville, New York, Court of Federal Claims No: 20–1685V
140. Frances Kraemer, Boston, Massachusetts, Court of Federal Claims No: 20–1687V
141. Jane Robinson, Boston, Massachusetts, Court of Federal Claims No: 20–1688V
142. Pavlo Chyshkevych and Nataliya Chyshkevych on behalf of R.C., Phoenix, Arizona, Court of Federal Claims No: 20–1689V
143. Janet Burgo, Atlanta, Georgia, Court of Federal Claims No: 20–1691V
144. Reginald Holmes, Clermont, Florida, Court of Federal Claims No: 20–1693V
145. Jean Cefalu, New Orleans, Louisiana, Court of Federal Claims No: 20–1694V
146. Joel Nichols, North Billerica, Massachusetts, Court of Federal Claims No: 20–1695V
147. Paul Wooters, Southlake, Texas, Court of Federal Claims No: 20–1696V
148. Deborah Liter, Madison, Indiana, Court of Federal Claims No: 20–1697V
149. Carrie Parent, Myrtle Beach, South Carolina, Court of Federal Claims No: 20–1698V
150. Charles Stella, New York, New York, Court of Federal Claims No: 20–1699V
151. Pamela Havice, Boston, Massachusetts, Court of Federal Claims No: 20–1701V
152. Anita Hall Darroca, Indianapolis, Indiana, Court of Federal Claims No: 20–1702V
153. Regis Grice, Waupun, Wisconsin, Court of Federal Claims No: 20–1703V
154. Stephen Vaccaro, Boston, Massachusetts, Court of Federal Claims No: 20–1704V
155. Bill Tackett, Jr., Lutz, Florida, Court of Federal Claims No: 20–1705V
156. Shakeyla Barber, Bronx, New York, Court of Federal Claims No: 20–1706V
157. Teresa Davis, Boston, Massachusetts, Court of Federal Claims No: 20–1707V
158. Clifford Gray, Antioch, Tennessee, Court of Federal Claims No: 20–1708V
159. Barbara Benson, Dresher, Pennsylvania, Court of Federal Claims No: 20–1709V
160. Nancy Dubrow, Beverly Hills, California, Court of Federal Claims No: 20–1710V

[FR Doc. 2020–28548 Filed 12–23–20; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Meeting of the Advisory Committee on Interdisciplinary, Community-Based Linkages

AGENCY: Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: In accordance with the Federal Advisory Committee Act, this notice announces that the Advisory Committee on Interdisciplinary, Community-Based Linkages (ACICBL) will hold public meetings for the 2021 calendar year (CY). Information about ACICBL, agendas, and materials for these meetings can be found on the ACICBL website at <https://www.hrsa.gov/advisory-committees/interdisciplinary-community-linkages/meetings/index.html>.

DATES: ACICBL meetings will be held on:

- January 14, 2021, 10:00 a.m.–5:00 p.m. Eastern Time (ET) and January 15, 2021, 10:00 a.m.–5:00 p.m. ET;
- February 17, 2021, 10:00 a.m.–5:00 p.m. ET; and
- August 5, 2021, 10:00 a.m.–5:00 p.m. ET.

ADDRESSES: Meetings may be held by teleconference, Adobe Connect webinar, and/or in-person. For updates on how the meetings will be held, visit the ACICBL website 30 business days before the date of the meeting, where instructions for joining meetings either in-person or remotely will also be posted. If a meeting is held in-person, it will be held at 5600 Fishers Lane, Rockville, Maryland 20857. For meeting information updates, go to the ACICBL website meeting page at <https://www.hrsa.gov/advisory-committees/interdisciplinary-community-linkages/index.html>.

FOR FURTHER INFORMATION CONTACT:

Shane Rogers, Designated Federal Official, Division of Medicine and Dentistry, Bureau of Health Workforce, HRSA, 5600 Fishers Lane, Room 15N142, Rockville, Maryland 20857; 301–443–5260; or SRogers@hrsa.gov.

SUPPLEMENTARY INFORMATION: The ACICBL provides advice and recommendations to the Secretary of HHS on policy, program development, and other matters of significance concerning the activities under sections 750–760, Title VII, Part D of the Public Health Service (PHS) Act. The ACICBL

submits an annual report to the Secretary of HHS and to Congress describing its activities, including findings and recommendations made by the ACICBL concerning the activities under sections 750–760 of the PHS Act.

Since priorities dictate meeting times, be advised that start times, end times, and agenda items are subject to change. For CY 2021 meetings, agenda items may include, but are not limited to, policy and program development and other significant matters related to activities authorized under Part D of the PHS Act as well as issues related to the pending Committee reports. Refer to the ACICBL website listed above for all current and updated information concerning the CY 2021 ACICBL meetings, including meeting times, draft agendas, and meeting materials that will be posted 30 calendar days before the meeting.

Members of the public will have the opportunity to provide comments. Public participants may submit written statements in advance of the scheduled meeting(s). Oral comments will be honored in the order they are requested and may be limited as time allows. Requests to submit a written statement or make oral comments to the ACICBL should be sent to Shane Rogers using the contact information above at least 5 business days before the meeting date(s).

Individuals who need special assistance or another reasonable accommodation should notify Shane Rogers using the contact information listed above at least 10 business days before the meeting(s) they wish to attend.

If a meeting is held in-person, it will occur in a federal government building and attendees must go through a security check to enter. Non-U.S. citizen attendees must notify HRSA of their planned attendance at an in-person meeting at least 20 business days prior to the meeting in order to facilitate their entry into the building. All attendees are required to present government-issued identification prior to entry.

Maria G. Button,

Director, Executive Secretariat.

[FR Doc. 2020-28466 Filed 12-23-20; 8:45 am]

BILLING CODE 4165-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Findings of research misconduct have been made against Yihong Wan, Ph.D. (Respondent), Associate Professor, Department of Pharmacology, University of Texas Southwestern Medical Center (UTSMC). Respondent engaged in research misconduct in research supported by U.S. Public Health Service (PHS) funds, specifically National Institute of Diabetes and Digestive and Kidney (NIDDK), National Institutes of Health (NIH), grant R01 DK089113. The administrative actions, including supervision for a period of three (3) years, were implemented beginning on December 8, 2020, and are detailed below.

FOR FURTHER INFORMATION CONTACT: Elisabeth A. Handley, Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 240, Rockville, MD 20852, (240) 453-8200.

SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

Yihong Wan, Ph.D., University of Texas Southwestern Medical Center: Based on the report of an investigation conducted by UTSMC and additional analysis conducted by ORI in its oversight review, ORI found that Respondent, Associate Professor, Department of Pharmacology, UTSMC, engaged in research misconduct in research supported by PHS funds, specifically NIDDK, NIH, grant R01 DK089113.

ORI found that Respondent engaged in research misconduct by intentionally, knowingly, and/or recklessly falsifying and/or fabricating bone histomorphometry data by altering or creating Excel data table values for additional bone samples that did not exist or were not analyzed and by falsely stating means and standard deviations calculated from experiments with N values

(i.e., number of mouse samples) that were larger than the actual N values in the following published paper:

- miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. *Nature* 2014;512(7515):431–5 (hereafter referred to as “*Nature* 2014”). Retraction in: *Nature* 2020 Jun;582(7810):134.

Specifically, ORI found that Respondent knowingly, intentionally, and/or recklessly falsified and/or fabricated bone histomorphometry data in eight (8) extended figures of one (1) published paper by manually falsifying and/or fabricating data values within

multiple Excel spreadsheets and by creating increased N values without testing additional samples. Specifically:

- In Extended Figure 1i of *Nature* 2014, Respondent fabricated female vertebrae histomorphometry data by multiplying fourteen (14) different numerical values representing male mouse vertebrae data by a factor of 0.95 to create female vertebrae values in one (1) Excel spreadsheet

- in Extended Figures 1i, 2d, 3d, 3h, 4h, 6a, 6e, and 9g of *Nature* 2014, Respondent falsified histomorphometry data for ninety-nine (99) data table values from two (2) Excel spreadsheets representing bone parameters for male distal femur, male vertebrae, female distal femur, and female vertebrae samples

- in Extended Figure 4h of *Nature* 2014, respondent fabricated bone histomorphometry data by reporting that the means and standard deviations were calculated from experiments with a value of six (6) to eight (8) mice per experimental condition, when respondent calculated the means and standard deviations from only three (3) mice (N = 3)

Dr. Wan entered into a Voluntary Settlement Agreement (Agreement) and agreed to the following:

(1) Respondent agreed to have her research supervised for a period of three (3) years beginning on December 8, 2020. Respondent agreed that prior to the submission of an application for PHS support for a research project on which Respondent’s participation is proposed and prior to Respondent’s participation in any capacity on PHS-supported research, Respondent shall ensure that a plan for supervision of Respondent’s duties is submitted to ORI for approval. The supervision plan must be designed to ensure the scientific integrity of Respondent’s research contribution. Respondent agreed that she shall not participate in any PHS-supported research until such a supervision plan is submitted to and approved by ORI. Respondent agreed to maintain responsibility for compliance with the agreed upon supervision plan.

(2) The requirements for Respondent’s supervision plan are as follows:

- A committee of 2–3 senior faculty members at the institution who are familiar with Respondent’s field of research, but not including Respondent’s supervisor or collaborators, will provide oversight and guidance for a period of three (3) years from the effective date of the Agreement. The committee will review primary data from Respondent’s laboratory on a quarterly basis and submit a report to ORI at six (6) month